SAN FRANCISCO--(BUSINESS WIRE)--Rezo Therapeutics, a biotechnology company pioneering the integrated mapping of disease networks for precision therapeutics, today announced the appointment of Nadir Mahmood, Ph.D., as chief executive officer and board member. Dr. Mahmood previously served as chief financial and business officer of Nkarta and brings significant leadership experience in corporate development, research and finance in the biopharmaceutical industry. Dr. Mahmood succeeds Rezo co-founder Nevan Krogan, Ph.D., who has served as interim chief executive officer and president since the company’s formation and will continue in the role of president.
“Nadir is a seasoned biotech leader and we are thrilled to welcome him to lead Rezo as our chief executive officer,” said Dr. Krogan. “This appointment underscores the strong progress we have made at Rezo in advancing our leading protein-protein interaction platform to create comprehensive, unprecedented maps of molecular disease networks to inform the development of a new wave of precision therapeutics.”
“Rezo’s platform integrates cutting-edge approaches in proteomics, genetics, structural biology, chemistry and machine learning to enable advanced insights into disease biology and how to modulate it for therapeutic discovery,” said Dr. Mahmood. “This is an incredible opportunity to lead a company that has the potential to fundamentally shift the way we understand disease biology by unlocking the universe of protein-protein interactions. This will allow us to approach drug discovery in a completely new way to develop new precision therapeutics for patients.”
Prior to Nkarta, Dr. Mahmood led corporate development at Second Genome, where he was responsible for establishing strategy and partnerships across the company’s portfolio of programs. Earlier in his career, he was a staff scientist at Kythera Biopharmaceuticals (acquired by Allergan), where he oversaw preclinical research for the company’s lead molecule, Kybella®. Dr. Mahmood has also worked in equity research at Goldman Sachs and consulted for early-stage companies in the life sciences and clean energy sectors. He earned a B.S. in biochemistry from the University of Texas at Austin and a Ph.D. in cell regulation from the University of Texas Southwestern Medical Center, and completed postdoctoral research at the Scripps Research Institute in La Jolla, CA.
About Rezo Therapeutics
Rezo is pursuing an integrated approach to drug discovery that leverages the multiple technologies and tools needed to bring disease networks into focus, pinpointing novel targets and therapies with more clarity. Rezo’s Sequence to Systems to Drugs platform integrates proteomics, genetics, structural biology, chemistry, artificial intelligence and machine learning to create maps of molecular disease networks. Based on the work of the founding team at the Quantitative Biosciences Institute (QBI) at the University of California, San Francisco (UCSF), the company’s mission is to break the mold in traditional drug development, which is slow and often siloed. The company’s initial focus is in oncology, with plans to explore additional therapeutic areas through collaborations and partnerships. To learn more, visit the company’s website at www.rezotx.com or its LinkedIn.
